E

    EyePoint, Inc (EYPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.50
    +0.02 (+0.45%)

    Market Cap: $375.61M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -21.43%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.91
    Range$-1.09 - $-0.60
    11 analysts
    EPS RevisionsNo revisions (7d)
    0
    6
    30d
    EPS Estimate Drift
    90d ago$-0.80+11.8%
    60d ago$-0.80+11.3%
    30d ago$-0.82+9.3%
    7d ago$-0.92-1.7%
    Current$-0.91
    Revenue Consensus
    $234080
    Range$0 - $600000
    13 analysts
    Dec 31, 2026
    EPS Consensus$-1.05
    Range$-1.70 - $-0.13
    11 analysts
    Revenue Consensus
    $761180
    Range$240800 - $2M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.05---
    Sep 26EST
    		-$-0.91---
    Jun 26
    		$-1.09$-0.92-18.48%Miss-28.2%
    Mar 26
    		$-0.99$-0.81-22.22%Miss-52.3%
    Dec 25
    		$-0.81$-0.75-8.33%Miss-26.6%
    Sep 25
    		$-0.85$-0.77-10.39%Miss-57.4%
    Jun 25
    		$-0.85$-0.80-6.25%Miss-46.6%
    Mar 25
    		$-0.65$-0.69+5.80%Beat-18.2%
    Dec 24
    		$-0.64$-0.48-34.31%Miss-93.9%
    Sep 24
    		$-0.54$-0.54+0.00%Beat-63.6%
    Jun 24
    		$-0.58$-0.51-13.73%Miss+4.9%
    Mar 24
    		$-0.55$-0.42-30.95%Miss+1.8%
    Dec 23
    		$-0.33$-0.49+32.65%Beat+71.6%
    Sep 23
    		$-0.33$-0.51+35.29%Beat+32.7%
    Jun 23
    		$-0.61$0.37-264.86%Miss-17.3%
    Mar 23
    		$-0.56$-0.65+13.85%Beat-7.7%
    Dec 22
    		$-1.16$-0.61-90.16%Miss-96.6%
    Sep 22
    		$-0.49$-0.69+28.99%Beat+15.5%
    Jun 22
    		$-0.52$-0.55+5.45%Beat-23.8%
    Mar 22
    		$-0.52$-0.59+11.86%Beat-4.0%
    Dec 21
    		$-0.59$-0.53-11.32%Miss+41.0%
    Sep 21
    		$-0.58$-0.40-45.00%Miss-93.3%
    Jun 21
    		$-0.42$-0.45+6.67%Beat+58.0%
    Mar 21
    		$-0.50$-0.50+0.00%Beat+54.5%
    Dec 20
    		$-1.00$-0.17-488.24%Miss+0.0%
    Sep 20
    		$-0.30$-0.30+0.00%Beat+80.0%
    Jun 20
    		$-1.00$-1.05+4.76%Beat+9.1%
    Mar 20
    		$-1.10$-0.95-15.79%Miss+31.3%
    Dec 19
    		$-1.00$-1.17+14.53%Beat+16.7%
    Sep 19
    		$-1.50$-1.37-9.49%Miss+21.1%
    Jun 19
    		$-1.10$-1.20+8.33%Beat+41.8%
    Mar 19
    		$-1.60$-1.37-16.79%Miss-56.9%
    Dec 18
    		$-1.20$-1.40+14.29%Beat+7.7%
    Sep 18
    		$-1.90$-1.47-29.25%Miss-26.7%
    Jun 18
    		$-1.89$-1.40-35.00%Miss-18.1%
    Mar 18
    		$-1.02$-1.20+15.00%Beat+32.0%
    Dec 17
    		$-1.30$-1.50+13.33%Beat-64900.0%
    Sep 17
    		$-1.50$-1.50+0.00%Beat+28.6%
    Jun 17
    		$-1.60$-1.50-6.67%Miss-
    Mar 17
    		$-1.50$-1.50+0.00%Beat-
    Dec 16
    		$-0.00N/A+99.89%Beat-
    Sep 16
    		$-2.10$-1.90-10.53%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.20EV/EBITDA11.56x
    Price/FCF-1.44xFCF Yield-69.66%
    Profitability
    Profit Margin0.00%Operating Margin-450.70%
    ROE-148.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.50xQuick Ratio4.46x
    Trading Statistics
    Beta1.74Avg Volume6.60M
    52-Week High$19.1152-Week Low$3.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.10
    SMA 20$8.72
    SMA 50$11.54
    SMA 200$13.78
    EMA 10$5.79
    EMA 20$7.68
    EMA 50$10.28
    EMA 200$12.35

    MACD

    Line: -2.26Signal: -1.88Hist: -0.38

    ADX

    ADX: 30.1+DI: 16.9-DI: 43.7

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down60.0
    PSAR$12.78

    Bollinger Bands

    Upper Band$17.10
    Lower Band$0.34
    %B Position19223%(Upper)
    Band Width0.25

    RSI (14-Day)

    Oversold
    28.2

    Momentum Oscillators

    Stoch %K5.4
    Stoch %D7.0
    Williams %R-94.9
    ROC (10d)-7.6%
    Momentum-0.37
    CCI (20d)-70.2
    MFI (14d)36.4

    Volatility Measures

    ATR (14d)$1.03(22.9%)
    StdDev (20d)4.19
    Hist Vol266.8%(High)

    Volume Flow

    VWAP$4.49
    OBV-23.9M
    AD Line69.4M
    CMF (20d)0.438

    Volume Metrics

    Avg Vol (20d)6.9M
    Vol Ratio0.5x
    VWMA (20d)$6.21

    Pivot Points

    R3$4.96
    R2$4.81
    R1$4.65
    Pivot Point$4.50
    S1$4.34
    S2$4.19
    S3$4.03

    Advanced Oscillators

    TSI-38.54
    Ultimate Osc34.5
    KST-537.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$507,000$696,000$619,000$966,000$5.33M$24.45M$11.59M$10.52M$9.48M$11.68M$14.03M$15.20M
    Cost of Revenue$0$0$2.07M$0$165,000$805,000$-1,495,000$736,000$0$759,000$-3,634,000$1.20M
    Gross Profit$507,000$696,000$-1,447,000$966,000$5.17M$23.65M$13.08M$9.79M$9.48M$10.93M$17.66M$14.00M
    Operating Expenses$97.89M$87.92M$68.90M$62.99M$67.39M$72.48M$58.32M$42.54M$44.02M$44.25M$34.02M$28.40M
    R&D$83.61M$72.15M$59.21M$47.75M$55.50M$58.57M$43.42M$29.54M$29.82M$30.14M$17.95M$17.36M
    SG&A$14.24M$15.24M$11.38M$14.49M$11.86M$13.88M$12.54M$12.97M$12.75M$14.10M$11.25M$10.56M
    Operating Income$-97,380,000$-87,226,000$-70,345,000$-62,025,000$-62,227,000$-48,837,000$-45,239,000$-32,748,000$-34,546,000$-33,321,000$-16,354,000$-14,398,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-94,470,000$-84,882,000$-67,423,000$-59,732,000$-59,333,000$-45,195,000$-41,309,000$-29,361,000$-30,826,000$-29,284,000$-14,016,000$-12,612,000
    Income Tax Expense$0$-50,000$0$0$93,000$0$0$0$0$0$0$0
    Net Income$-94,470,000$-84,832,000$-67,609,000$-59,732,000$-59,426,000$-45,195,000$-41,399,000$-29,361,000$-30,826,000$-29,284,000$-14,099,000$-12,612,000
    EBITDA$-93,970,000$-85,024,000$-67,635,000$-60,107,000$-59,996,000$-46,431,000$-42,638,000$-30,829,000$-32,156,000$-29,556,000$-14,426,000$-12,536,000
    EBIT$-94,470,000$-84,882,000$-67,390,000$-59,732,000$-59,333,000$-45,195,000$-41,295,000$-29,361,000$-30,826,000$-29,284,000$-14,016,000$-12,612,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EYPT

    News

    Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)

    Levi & Korsinsky is investigating potential securities claims against EyePoint Pharmaceuticals (EYPT) after its shares dropped nearly 67% following the failure of its DURAVYU Phase 3 LUGANO trial. The law firm is encouraging shareholders who suffered losses to have their legal rights reviewed, as the company's previous statements about the trial's confidence are under scrutiny. Investors do not incur upfront costs for the review, and eligibility is based on purchase date and documented losses, not current shareholding.

    GlobeNewswire•8/24/26•
    Bearish

    OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

    Shares of Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) rallied after rival EyePoint Pharmaceuticals (EYPT) reported a setback in its late-stage trial for an eye implant to treat wet age-related macular degeneration. Analysts believe EyePoint's trial failure eases competition for Ocular's similar drug Axpaxli and improves the outlook for 4D Molecular's 4D-150 gene therapy. While EyePoint's stock plummeted, OCUL and FDMT experienced their best trading days in weeks.

    Stocktwits•8/24/26•
    Bearish

    EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

    SueWallSt.com has announced an investigation into EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant 67% stock drop after its DURAVYU drug failed to meet its primary endpoint in a Phase 3 trial for wet AMD. The firm is inviting investors who suffered losses to submit their information for a potential securities fraud claim, questioning whether EyePoint made misleading statements about the trial's progress. This investigation highlights concerns about the company's prior assurances regarding the drug's potential before disclosing the trial's failure.

    PR Newswire•8/20/26•
    Bearish

    Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold"

    Royal Bank of Canada downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from "moderate buy" to "hold," and Cantor Fitzgerald also shifted to a neutral rating. This follows the company's DURAVYU trial missing its primary endpoint, leading to a sharp stock decline and concerns about its future regulatory and commercial success. Despite some analysts maintaining "buy" ratings, the consensus among analysts tracked by MarketBeat is now "Hold" with an average price target of $28.11.

    MarketBeat•8/19/26•
    Bearish

    EYPT Stock Crashes On Duravyu Data But Catalysts Loom

    EyePoint Pharmaceuticals (EYPT) stock initially crashed by 69% after its Phase 3 LUGANO trial for DURAVYU in wet AMD missed its primary vision endpoint on the full dataset. However, an ad hoc analysis, excluding an asymmetric cohort, showed non-inferiority against aflibercept and other strong secondary outcomes, leading to a rebound. Despite a wider Q2 EPS loss, the company has significant cash reserves and upcoming catalysts, including topline data for the LUCIA trial in Q4 2026 and potential NDA submission in 2027.

    StocksToTrade•8/18/26•
    Neutral

    Frequently Asked Questions About EYPT

    Does EYPT pay dividends?
    EyePoint, Inc (EYPT) does not currently pay a regular dividend.
    What is EYPT's market cap?
    EyePoint, Inc (EYPT) has a market capitalization of $375.61M with a current stock price of $4.50.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In